年轻BRCA携带者乳腺癌患者中降低风险手术与生存的关联:一项国际队列研究
这项国际、医院为基础的回顾性队列研究纳入2000年1月1日至2020年12月31日在五大洲109个中心诊断的40岁及以下I-III期浸润性乳腺癌的胚系BRCA1/BRCA2致病性或可能致病性变异携带者5290例,评估降低风险乳房切除术(RRM)或降低风险输卵管卵巢切除术(RRSO)与总生存的关联。中位随访8.2年(IQR 4.7-12.8),RRM与更好的总生存相关(校正HR 0.65,95%CI 0.53-0.78),RRSO亦与更好的总生存相关(校正HR 0.58,95%CI 0.48-0.71)。
要点
- 在5290例年轻BRCA携带者乳腺癌患者中,RRM与更好的总生存显著相关(校正HR 0.65,95%CI 0.53-0.78)。
- RRSO同样与更好的总生存显著相关(校正HR 0.58,95%CI 0.48-0.71)。
- 20年限制性平均总生存时间:RRM组17.89年 vs 无RRM组16.65年;RRSO组17.73年 vs 无RRSO组16.67年。
核心结论
- 在这项全球年轻乳腺癌BRCA携带者队列中,RRM和RRSO均与总生存的显著改善相关。
- 这些发现为这一独特高危患者群体的癌症风险管理策略的个体化咨询提供了证据。
研究设计与样本
- BRCA BCY协作组是一项国际、医院为基础的回顾性队列研究,在五大洲109个中心开展。
- 纳入2000年1月1日至2020年12月31日诊断的40岁及以下、I-III期浸润性乳腺癌、携带胚系BRCA1或BRCA2或两者致病性或可能致病性变异的女性。
- 共纳入5290例患者,其中3361例(63.5%)为BRCA1致病性变异携带者,2708例(51.2%)为淋巴结阴性,2421例(45.8%)为激素受体阳性乳腺癌。
- 2910例(55.0%)接受RRM,2782例(52.6%)接受RRSO。
- 主要终点为总生存;本研究注册于ClinicalTrials.gov,NCT03673306。
主要发现
- 中位随访8.2年(IQR 4.7-12.8),RRM与无RRM相比与显著更好的总生存相关(校正HR 0.65,95%CI 0.53-0.78)。
- 20年限制性平均总生存时间:RRM组17.89年(95%CI 17.61-18.17) vs 无RRM组16.65年(95%CI 16.38-16.92)。
- RRSO与无RRSO相比亦与显著更好的总生存相关(校正HR 0.58,95%CI 0.48-0.71)。
- 20年限制性平均总生存时间:RRSO组17.73年(95%CI 17.43-18.03) vs 无RRSO组16.67年(95%CI 16.38-16.96)。
临床怎么用
- 作者认为,这些发现为这一独特高危患者群体的癌症风险管理策略的个体化咨询提供了证据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little evidence exists on the effect of risk-reducing surgeries in young BRCA carriers with a previous history of breast cancer. We investigated the association between risk-reducing mastectomy (RRM) or risk-reducing salpingo-oophorectomy (RRSO), or both procedures, with survival outcomes in a large global cohort of young BRCA carriers with previous breast cancer. METHODS: The BRCA BCY Collaboration is an international, hospital-based, retrospective cohort study, conducted at 109 centres in five continents, including women harbouring germline BRCA1, BRCA2, or both, pathogenic or likely pathogenic variants and diagnosed with stage I-III invasive breast cancer at the age of 40 years or younger between Jan 1, 2000, and Dec 31, 2020. The primary objectives of the present analysis were to determine the association between RRM or RRSO and overall survival in young BRCA carriers with breast cancer. The primary endpoint was overall survival. This study is registered with ClinicalTrials.gov, NCT03673306. FINDINGS: Between Jan 1, 2000 and Dec 31, 2020, 5290 patients were included, of whom 3361 (63·5%) patients were BRCA1 pathogenic variant carriers, 2708 (51·2%) had node-negative, and 2421 (45·8%) hormone receptor-positive breast cancer. Of 5290 patients, 2910 (55·0%) underwent RRM, 2782 (52·6%) underwent RRSO. After a median follow-up of 8·2 years (IQR 4·7-12·8), RRM was associated with significantly better overall survival compared with no RRM (adjusted HR [aHR] 0·65, 95% CI 0·53-0·78; 20-year restricted mean overall survival time 17·89 years [95% CI 17·61-18·17] with RRM vs 16·65 years [16·38-16·92] without RRM). RRSO was also associated with significantly better overall survival compared with no RRSO (aHR 0·58, 95% CI 0·48-0·71; 20-year restricted mean overall survival time 17·73 years [95% CI 17·43-18·03] with RRSO vs 16·67 years [16·38-16·96] without RRSO). INTERPRETATION: In this global cohort of BRCA carriers with previous breast cancer diagnosis at a young age, RRM and RRSO were both associated with a significant improvement in overall survival. These findings provide evidence for a tailored counselling of a unique and high-risk patient population on cancer risk management strategies. FUNDING: Italian Association for Cancer Research.
引用
- Blondeaux E, Sonnenblick A, Agostinetto E, et al. Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study. Lancet Oncol. 2025. PMID: 40347973. doi:10.1016/S1470-2045(25)00152-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。